Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

Korábbi kezelés

• Subjects with a history of or current comorbidities including:
  • Hematologic malignancies, such as lymphoma, or any other malignant tumors apart from the indication of this study.
  • Subjects with the cardiovascular conditions such as unstable angina and/or myocardial infarction within 1 year prior to screening
  • Subjects with the pulmonary baseline conditions:
  • Blood coagulation disorder
  • Active bleeding disorders (including gastrointestinal bleeding)
• Subjects who have received antithrombotics, including antiplatelets or anticoagulants
• Subjects who have received anticancer therapies within 28 days prior to trial participation, or who have not recovered or stabilized from all AEs caused by such treatments to baseline levels
• Subjects who have received radical radiotherapy within 6 weeks prior to trial participation etc.
• Subjects who have received live vaccines or attenuated vaccines within 4 weeks prior to study participation
• Subjects who have previously received intratumoral therapy for the target lesion

Más betegség

• Subjects must not meet any of the following conditions:
• Subjects with active HBV or HCV, or HIV positive
• Subjects with severe infections requiring antibiotics, antifungal agents, or antiviral agents, or those with uncontrolled active infectious diseases
• Subjects with any form of primary immunodeficiency or active autoimmune diseases

Egyéb

• Ineligibility or inability to participate in the study at the investigator's discretion

• Adults aged ≥19 years, male or female
• Subject with histologically and/or cytologically confirmed, unresectable advanced NSCLC for radical cure that are confirmed as PD for the standard of care currently known to have clinical benefits, or for which no currently available standard of care exists due to intolerance, ineligibility, treatment refusal, etc.
• Subjects must have at least one evaluable and injectable lesion as assessed on CT images based on RECIST version 1.1.
• Subjects with valid biopsy results documented the presence of KRAS mutation.
• Subjects with an ECOG performance status of 0 or 1 and an expected survival of at least 12 weeks at the time of study participation.
• Subjects with adequate hematologic and terminal organ function.
• Subjects must voluntarily sign an informed consent form approved by the IRB. Subjects must have the willingness and ability to comply with all procedures required by the protocol.